Billiontoone (NASDAQ:BLLN) Given New $100.00 Price Target at Guggenheim

Billiontoone (NASDAQ:BLLN) had its price target lowered by Guggenheim from $120.00 to $100.00 in a report issued on Monday,Benzinga reports. Guggenheim currently has a buy rating on the stock.

A number of other research firms have also weighed in on BLLN. BTIG Research reduced their price objective on Billiontoone from $160.00 to $140.00 and set a “buy” rating for the company in a research report on Thursday, March 5th. Weiss Ratings began coverage on Billiontoone in a report on Tuesday, February 3rd. They issued a “sell (d)” rating on the stock. Jefferies Financial Group assumed coverage on Billiontoone in a research note on Monday, December 1st. They issued a “hold” rating and a $117.00 target price on the stock. JPMorgan Chase & Co. lowered their price target on Billiontoone from $150.00 to $145.00 and set an “overweight” rating for the company in a research report on Wednesday, December 10th. Finally, Zacks Research upgraded shares of Billiontoone to a “hold” rating in a research note on Tuesday, December 2nd. Six analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Billiontoone has an average rating of “Moderate Buy” and a consensus price target of $126.71.

Billiontoone Price Performance

NASDAQ:BLLN opened at $70.11 on Monday. The company has a market capitalization of $3.22 billion and a price-to-earnings ratio of 333.86. The company has a debt-to-equity ratio of 0.12, a current ratio of 11.69 and a quick ratio of 11.32. Billiontoone has a one year low of $61.96 and a one year high of $138.70. The business’s 50-day simple moving average is $79.73.

Billiontoone (NASDAQ:BLLN) last announced its earnings results on Wednesday, March 4th. The company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.07. The business had revenue of $96.05 million for the quarter, compared to the consensus estimate of $85.85 million. The firm’s revenue for the quarter was up 113.0% compared to the same quarter last year.

Hedge Funds Weigh In On Billiontoone

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Green Alpha Advisors LLC purchased a new stake in Billiontoone during the 4th quarter valued at $436,000. FNY Investment Advisers LLC purchased a new position in shares of Billiontoone in the fourth quarter worth $497,000. Massachusetts Financial Services Co. MA purchased a new position in shares of Billiontoone in the fourth quarter worth $13,373,000. Baillie Gifford & Co. bought a new position in shares of Billiontoone during the fourth quarter valued at $103,786,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Billiontoone during the fourth quarter valued at $1,348,000.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.